Technical Analysis for MRUS - Merus N.V.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 42.93 | -1.29% | -0.56 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Lower Bollinger Band Walk | Weakness | -1.29% | |
| Below Lower BB | Weakness | -1.29% | |
| Down 3 Days in a Row | Weakness | -1.29% |
| Alert | Time |
|---|---|
| Possible NR7 | about 18 hours ago |
| 60 Minute Opening Range Breakdown | about 18 hours ago |
| Fell Below Previous Day's Low | about 21 hours ago |
| Down 2 % | about 21 hours ago |
| Down 1% | about 22 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 10/31/2024
Merus N.V. Description
Merus B.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, colorectal, and ovarian cancers. The company also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies. Its pre-clinical bispecific antibody candidates include MCLA-134, MCLA-114, and MCLA-145, as well as other early research projects. The company has a strategic collaboration with Gustave Roussy to develop innovative bispecific antibodies for therapeutic immuno-oncology applications. Merus B.V. was founded in 2003 and is headquartered in Utrecht, the Netherlands.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Immunology Solid Tumors Antibodies Cancer Immunotherapy Monoclonal Antibodies Acute Myeloid Leukemia Ovarian Cancer Myelodysplastic Syndrome Monoclonal Antibody Therapy Oncology Applications Novimmune Treatment Of Myelodysplastic Syndrome
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
View full discussion...
| Indicator | Value |
|---|---|
| 52 Week High | 61.61 |
| 52 Week Low | 22.26 |
| Average Volume | 499,796 |
| 200-Day Moving Average | 49.63 |
| 50-Day Moving Average | 50.58 |
| 20-Day Moving Average | 50.46 |
| 10-Day Moving Average | 49.15 |
| Average True Range | 2.10 |
| RSI (14) | 25.37 |
| ADX | 18.95 |
| +DI | 14.36 |
| -DI | 37.86 |
| Chandelier Exit (Long, 3 ATRs) | 49.08 |
| Chandelier Exit (Short, 3 ATRs) | 48.61 |
| Upper Bollinger Bands | 57.21 |
| Lower Bollinger Band | 43.71 |
| Percent B (%b) | -0.06 |
| BandWidth | 26.76 |
| MACD Line | -1.74 |
| MACD Signal Line | -0.61 |
| MACD Histogram | -1.1305 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 44.76 | ||||
| Resistance 3 (R3) | 44.75 | 44.14 | 44.46 | ||
| Resistance 2 (R2) | 44.14 | 43.67 | 44.14 | 44.35 | |
| Resistance 1 (R1) | 43.53 | 43.38 | 43.23 | 43.54 | 44.25 |
| Pivot Point | 42.92 | 42.92 | 42.76 | 42.92 | 42.92 |
| Support 1 (S1) | 42.31 | 42.45 | 42.01 | 42.32 | 41.61 |
| Support 2 (S2) | 41.70 | 42.16 | 41.70 | 41.51 | |
| Support 3 (S3) | 41.09 | 41.70 | 41.41 | ||
| Support 4 (S4) | 41.10 |
